New Developments in Neurofibromatosis Type 2
2019 AAO-HNSF Annual Meeting & OTO Experience
Keyword(s)
neurofibromatosis type 2, optimal hearing, facial nerve preservation
Patients with neurofibromatosis type 2 (NF2) present difficult treatment conundrums. The purpose of this session is to 1) share new potential medical treatments which have emerged in the past two years for the treatment of NF2, 2) to give an update on recent and current clinical trials, 3) to discuss standardized outcomes measurements for those wishing to participate in clinical trials, and 4) to discuss minimizing morbidity and maximizing outcomes for our patients.
Description
Patients with neurofibromatosis type 2 (NF2) present difficult treatment conundrums. The purpose of this session is to 1) share new potential medical treatments which have emerged in the past two years for the treatment of NF2, 2) to give an update on recent and current clinical trials, 3) to discuss standardized outcomes measurements for those wishing to participate in clinical trials, and 4) to discuss minimizing morbidity and maximizing outcomes for our patients.Learning Objectives: 1. Discuss current clinical trials in NF2. 2. Identify new drugs available for the treatment of NF2. 3. Prioritize to minimize mortality and morbidity including optimal hearing and facial nerve preservation.Faculty: D Bradley Welling, MD, PhD(Consulting Fees: Astellas), Konstantina Stankovic, MD, PhD, FACS(Did Not Disclose).
Courses in package:
No Records Found
